Convergent QSAR studies on a series of NK₃ receptor antagonists for schizophrenia treatment

J Enzyme Inhib Med Chem. 2016;31(2):283-94. doi: 10.3109/14756366.2015.1021250. Epub 2015 Apr 9.

Abstract

The dopamine hypothesis states that decreased dopaminergic neurotransmission reduces schizophrenia symptoms. Neurokinin-3 receptor (NK3) antagonists reduce dopamine release and have shown positive effects in pre-clinical and clinical trials. We employed 2D and 3D-QSAR analysis on a series of 40 non-peptide NK3 antagonists. Multivariate statistical analysis, PCA and HCA, were performed to rational training/test set splitting and PLS regression was employed to construct all QSAR models. We constructed one highly predictive CoMFA model (q(2)= 0.810 and r(2)= 0.929) and acceptable HQSAR and CoMSIA models (HQSAR q(2)= 0.644 and r(2)= 0.910; CoMSIA q(2)= 0.691, r(2)= 0.911). The three different techniques provided convergent physicochemical results. All models indicate cyclopropane, piperidine and di-chloro-phenyl ring attached to cyclopropane ring and also the amide group attached to the piperidine ring could play an important role in ligand-receptor interactions. These findings may contribute to develop potential NK3 receptor antagonists for schizophrenia.

Keywords: CoMFA; CoMSIA; HQSAR; NK3 receptor antagonists; schizophrenia.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cyclopropanes / chemistry
  • Humans
  • Piperidines / chemistry
  • Quantitative Structure-Activity Relationship*
  • Receptors, Neurokinin-3 / antagonists & inhibitors*
  • Schizophrenia / drug therapy*

Substances

  • Cyclopropanes
  • Piperidines
  • Receptors, Neurokinin-3
  • piperidine
  • cyclopropane